HOME >> BIOLOGY >> NEWS
Surveillance and containment would be effective intervention against deliberate smallpox attack

SEATTLE -- In the event of a large, intentional release of smallpox, the current government policy of post-release surveillance and containment, if quickly implemented, would be sufficient to prevent a widespread epidemic, according to a study by biostatisticians at Emory University's Rollins School of Public Health. Surveillance and containment consist of isolating known cases and vaccinating close contacts.

Delays in isolating cases by even one or two days, however, could hamper control of an epidemic, according to research by Ira M. Longini, Jr., PhD and M. Elizabeth Halloran, MD, Sc, Emory professors of biostatistics and their colleagues Azhar Nizam and Yang Yang, Dr. Longini will present the research at the AAAS Annual Meeting in Seattle on February 14.

Although mass vaccination during or before a smallpox attack would result in fewer cases and deaths than would surveillance and containment, the researchers concluded that an increased rate of vaccine-related serious illness and death would offset the slightly lower number of smallpox illnesses and deaths, especially since no one knows when or where an intentional release of smallpox would take place. The scientists also concluded that even if a particular smallpox virus were altered to cause more serious, or hemorrhagic cases than the ordinary virus, surveillance and containment would still be effective, although more deaths would occur.

In an earlier study (Science, Nov. 15 2002), the researchers concluded that targeted vaccination of the close contacts of infected individuals during a smallpox outbreak following a small attack could rival the effectiveness of mass vaccination, given a sufficiently high level of immunity within the population. However, as of May, 2003, fewer than 35,000 people had been newly vaccinated against smallpox, and many states had temporarily halted their smallpox vaccination programs. Although routine smallpox vaccinations were stopped in 1972, re
'"/>

Contact: Tia Webster
twebste@emory.edu
404-727-5692
Emory University Health Sciences Center
14-Feb-2004


Page: 1 2 3

Related biology news :

1. Protecting the Beat Of Life: Test Center Studies Interaction Between Pacemakers & Electronic Article Surveillance Systems
2. Hopkins Engineering Undergrads Inventions: Power Tools For Double Amputee, Military Surveillance Robot
3. Conserving hydrocarbons would save $438 billion
4. Sediment samples suggest how plants would fare in hotter, drier future
5. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
6. Endurance exercise found to be equally effective as diuretics in improving cardiac health
7. Purdue yeast makes ethanol from agricultural waste more effectively
8. Scientists learn how adjuvant makes vaccines effective
9. Super-effective jumping gene created
10. Drug combo effective in advanced breast cancer
11. Data show investigational antibiotic safe, effective in preventing travelers diarrhea

Post Your Comments:
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/19/2015)... 19, 2015  VOXX International Corporation (Nasdaq: ... into a Definitive Agreement to purchase the assets, ... market leader EyeLock through an acquiring entity.  Upon ... controlling interest in the acquiring entity. The closing ... due diligence.  Expanding on its existing supply chain ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... HONG KONG , Aug. 26, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... Holdings Limited ("MO2"), an entity wholly owned by Mr. ... the Company, has acquired the outstanding shares (the "Shares") ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, ... new business relationships with local sponsors in southern California. The Clinical Trial Management Expert ... development processes and regulatory pathways., , Stem Cell Meeting ...
(Date:8/25/2015)... ... August 25, 2015 , ... A new optical ... is described by University of Illinois researchers in the Journal of Biomedical ... In “ Breast cancer diagnosis using spatial light interference microscopy ,” published 20 ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
Cached News: